Baird analyst Brian Skorney is incrementally positive on Proteostasis Therapeutics' (NASDAQ: PTI) FDA breakthrough designation for PTI-428.Skorney said the FDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Proteostasis Therapeutics (PTI) Surges 50% on FDA Breakthrough Therapy Designation for PTI-428March 13, 2018 9:05 AM Proteostasis Therapeutics (PTI) Announces FDA Breakthrough Therapy Designation for PTI-428 in CFMarch 12, 2018 4:14 PM Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic FibrosisMarch 12, 2018 4:05 PM